Literature DB >> 590852

Association of abnormal fibrin polymerisation with severe liver disease.

G Green, L Poller, J M Thomson, I W Dymock.   

Abstract

The frequent occurrence of abnormal fibrin polymerisation in patients with liver disease has recently been reported. To investigate this further, fibrin polymerisation was studied in 68 patients with cirrhosis or chronic active liver disease. Thirty-three of these patients demonstrated impairment of this phase of blood coagulation. When other tests of liver function were compared in patients demonstrating this abnormality and those in whom fibrin polymerisation was normal, it was found that the former group demonstrated significantly reduced albumin concentrations (p less than 0.0002), raised bilirubin and aspartate aminotransferase levels (p less than 0.0006 and less than 0.003 respectively), and greater prolongation of the one-stage prothrombin time (p less than 0.001) with more marked reduction in factor VII levels (p less than 0.002) compared with the latter patients. It is concluded that defective fibrin polymerisation occurring in patients with liver disease indicates the presence of severely impaired hepatocellular function. This might account for the grave prognosis reported in cirrhotic patients with abnormal fibrin polymerisation who also suffer bleeding from gastro-oesophageal varices.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590852      PMCID: PMC1411733          DOI: 10.1136/gut.18.11.909

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Proceedings: Abnormal fibrin monomer polymerization in liver disease.

Authors:  G Green; J M Thomson; L Poller; I W Dymock
Journal:  Gut       Date:  1975-10       Impact factor: 23.059

2.  Coagulation studies as a prognostic index in acute liver failure.

Authors:  I W Dymock; J S Tucker; I L Woolf; L Poller; J M Thomson
Journal:  Br J Haematol       Date:  1975-03       Impact factor: 6.998

3.  COAGULATION STUDIES IN LIVER DISEASE.

Authors:  A HALLEN; I M NILSSON
Journal:  Thromb Diath Haemorrh       Date:  1964-04-15

4.  A rapid "side-room" method for the determination of plasma fibrinogen concentration as fibrin.

Authors:  G I INGRAM; M O MATCHETT
Journal:  J Clin Pathol       Date:  1960-11       Impact factor: 3.411

5.  Dysfibrinogenaemia and primary hepato-cellular carcinoma.

Authors:  R D Barr; N Ouna; J G Simpson; A F Bagshawe
Journal:  Q J Med       Date:  1976-10

6.  [Acquired dysfibrinogenemia and hepatic disorders. Apropos of 30 cases].

Authors:  M Aiach; J Rogé; M F Busy; H Durand; N Guéroult; C Chanrion; M Leclerc; L Justin-Besançon
Journal:  Sem Hop       Date:  1973-01-14

7.  Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.

Authors:  A von Felten; P W Straub; P G Frick
Journal:  N Engl J Med       Date:  1969-02-20       Impact factor: 91.245

8.  Factor VII as a marker of hepatocellular synthetic function in liver disease.

Authors:  G Green; L Poller; J M Thomson; I W Dymock
Journal:  J Clin Pathol       Date:  1976-11       Impact factor: 3.411

9.  Abnormal fibrin polymerization in liver disease.

Authors:  G Green; J M Thomson; I W Dymock; L Poller
Journal:  Br J Haematol       Date:  1976-11       Impact factor: 6.998

10.  Synthesis of all plasma protein fractions except gamma globulins by the liver; the use of zone electrophoresis and lysine-epsilon-C14 to define the plasma proteins synthesized by the isolated perfused liver.

Authors:  L L MILLER; W F BALE
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

View more
  1 in total

1.  Acquired dysfibrinogenaemia in liver disease.

Authors:  J L Francis; D J Armstrong
Journal:  J Clin Pathol       Date:  1982-06       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.